In this 52-week trial, 47.2% of patients in the lorcaserin group lost at least 5% of their body weight, compared to 25% of patients in the placebo group [84]
Established risk factors include: History of pancreatitis: Patients with prior episodes face substantially higher recurrence risk and require careful consideration before initiating GLP-1 therapy Gallstone disease: Cholelithiasis and biliary sludge can precipitate pancreatitis, particularly during periods of rapid weight loss Hypertriglyceridemia: Triglyceride levels 1,000 mg/dL significantly increase pancreatitis risk, with risk beginning to rise at levels 500 mg/dL Excessive alcohol consumption: Alcohol remains one of the most common pancreatitis triggers and may interact with metabolic changes induced by GLP-1 medications Obesity and rapid weight loss: While weight reduction is therapeutic, very rapid loss may increase gallstone formation Warning signs of acute pancreatitis that patients should recognize include severe, persistent abdominal pain, typically in the upper abdomen and often radiating to the back
It was a time when the smell of searing offal permeated hospital wards and providing patients with a varied diet was a challenge to hospital caterers
Results vary depending on the peptide used and your bodys baseline function
Kashani, L., Aslzadeh, S., Shokraee, K., Shamabadi, A., Najafabadi, B
*Correspondence: Hitoshi Ando, [email protected] This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
